Document is current
Any future updates will be listed below
-
Authors
Mohammad, Anas
Iversen, Ditte Bork https://orcid.org/0000-0002-5519-9091
Rausgaard, Nete Lundager Klokker https://orcid.org/0000-0003-1662-3547
Kruuse, Christina https://orcid.org/0000-0002-4210-0523
Beier, Dagmar https://orcid.org/0000-0002-3336-157X
Stage, Tore Bjerregaard https://orcid.org/0000-0002-4698-4389
Pellesi, Lanfranco https://orcid.org/0000-0003-4137-5039
-
Funding
Funding for this research was provided by:
Oda og Hans Svenningsens Fond
Torben og Alice Frimodts Fond
A.P. Møller Fond
- License Information
-
More Information
Article History
Received: 16 November 2025
Accepted: 19 December 2025
First Online: 10 January 2026
Declarations
:
: DB reported receiving personal fees from Novartis, Pfizer, Lilly, Teva, Lundbeck and Abbvie; receiving travel support from Allergan/Abbvie, Teva, Pfizer and Lundbeck; and participating in clinical trials supported by Teva, Lundbeck, Novartis, Lilly, and Novo Nordisk Foundation outsidethe submitted work. TBS has given paid lectures for Pfizer and Eisai, he has done consulting for Pfizer, he acted as an expert witness on the behalf of Sandoz A/S and he collaborated with Novo Nordisk A/S, all unrelated to the work reported in the present paper. LP serves as member of the Editorial Board of Clinical and Translational Science, The Journal of Headache and Pain, BMC Neurology, Pain Research and Management, European Journal of Medical Research and Brain Conflux. AM, DBI, NLKR and CK declare no competing interests.
